|
Ben-Efraim, S (2001) Immunomodulating anticancer alkylating drugs: targets and mechanisms of activity. Curr Drug Targets 2:197-212
|
|
Ben-Efraim, S (1999) One hundred years of cancer immunotherapy: a critical appraisal. Tumour Biol 20:1-24
|
|
Ben-Efraim, S (1996) Cancer immunotherapy: hopes and pitfalls: a review. Anticancer Res 16:3235-40
|
|
Laude, M; Russo, K L; Mokyr, M B et al. (1993) Cure of mice bearing a late-stage, highly metastatic, drug-resistant tumor by adoptive chemoimmunotherapy. Cancer Immunol Immunother 36:229-36
|
|
Laude, M; Russo, K L; Mokyr, M B et al. (1993) Two tumor models of curative adoptive chemoimmunotherapy using tumor-infiltrated spleen cells with potent antitumor cytotoxicity stimulated by antigen-sharing tumors. Cancer Immunol Immunother 37:89-96
|
|
Laude, M; Siessmann, K L; Mokyr, M B et al. (1991) Advantages of adoptive chemoimmunotherapy with polyethylene glycol-cultured, antigen-activated, tumor-infiltrated spleen cells for the complete eradication of lethal MOPC-315 plasmacytomas. Cancer Res 51:4516-22
|
|
Barker, E; Wise, J A; Dray, S et al. (1989) Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers. Cancer Res 49:5007-15
|
|
Wise, J A; Mokyr, M B; Dray, S (1989) Enhancement of the effectiveness of Lyt-2+ T-cells for adoptive chemoimmunotherapy by short-term exposure of tumor-bearer spleen cells to polyethylene glycol and/or melphalan. Cancer Res 49:3613-9
|
|
Dray, S; Mokyr, M B (1989) Cyclophosphamide and melphalan as immunopotentiating agents in cancer therapy. Med Oncol Tumor Pharmacother 6:77-85
|
|
Wise, J A; Mokyr, M B; Dray, S (1988) Effect of low-dose cyclophosphamide therapy on specific and nonspecific T cell-dependent immune responses of spleen cells from mice bearing large MOPC-315 plasmacytomas. Cancer Immunol Immunother 27:191-7
|
Showing the most recent 10 out of 17 publications
